TY  - JOUR
AU  - Fernández-Juárez, Gema
AU  - Rojas-Rivera, Jorge
AU  - Logt, Anne-Els van de
AU  - Justino, Joana
AU  - Sevillano, Angel
AU  - Caravaca-Fontán, Fernando
AU  - Ávila, Ana
AU  - Rabasco, Cristina
AU  - Cabello, Virginia
AU  - Varela, Alfonso
AU  - Díez, Montserrat
AU  - Martín-Reyes, Guillermo
AU  - Diezhandino, Marian Goicoechea
AU  - Quintana, Luis F
AU  - Agraz, Irene
AU  - Gómez-Martino, Juan Ramón
AU  - Cao, Mercedes
AU  - Rodríguez-Moreno, Antolina
AU  - Rivas, Begoña
AU  - Galeano, Cristina
AU  - Bonet, Jose
AU  - Romera, Ana
AU  - Shabaka, Amir
AU  - Plaisier, Emmanuelle
AU  - Espinosa, Mario
AU  - Egido, Jesus
AU  - Segarra, Alfonso
AU  - Lambeau, Gérard
AU  - Ronco, Pierre
AU  - Wetzels, Jack
AU  - Praga, Manuel
AU  - STARMEN Investigators
PY  - 2020
DO  - 10.1016/j.kint.2020.10.014
UR  - https://hdl.handle.net/10668/25927
T2  - Kidney international
AB  - A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical alternating...
LA  - en
KW  - corticosteroids
KW  - cyclophosphamide
KW  - primary membranous nephropathy
KW  - rituximab
KW  - tacrolimus
KW  - Adrenal Cortex Hormones
KW  - Cyclophosphamide
KW  - Glomerulonephritis, Membranous
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Rituximab
KW  - Tacrolimus
KW  - Treatment Outcome
TI  - The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
TY  - research article
VL  - 99
ER  -